The challenge of HIV is vast, and the need for a coordinated effort against it is great. Merck remains committed to the long-term battle against this disease. For more than 25 years, we have sought to make a difference through research, access programs and collaborations with a range of stakeholders. Although our commitment to access in HIV has remained the same for decades, our approach has not. We continually refine our strategy, so that we incorporate the lessons we've learned and make meaningful improvements.
We recognize that collaboration is a hallmark of much of the progress made against HIV, and that access to care is about more than the cost of medicines. Our commitment to working with governments, donors, innovator and generic manufacturers, multilateral organizations and civil society to address the full range of factors affecting access is strong. Since 1985, we've conducted extensive research in HIV, and have helped to broaden access through a strategy built upon expanded availability of medicines, enhanced access strategies and local community support.
Read more about our global HIV access strategy in our corporate responsibility report.